BioCentury
ARTICLE | Clinical News

HQK-1001: Completed Phase IIb enrollment

June 17, 2013 7:00 AM UTC

HemaQuest completed enrollment of 77 patients in a double-blind, placebo-controlled, international Phase IIb trial evaluating twice-daily oral HQK-1001 for 48 weeks. The compound has Orphan Drug desig...